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RWe note with great interest the publication by
tern et al, which evaluated the hypothesis that human
eukocyte antigen (HLA) DR15 would reduce relapse
ate and improve survival in patients receiving alloge-
eic stem cell transplantation [1]. We had previously
xamined this hypothesis in our single center study of
19 consecutive related and 48 consecutive unrelated
yeloablative allogeneic blood and marrow transplant
BMT) for myeloid malignancies to investigate the
nﬂuence of HLA DR15 on overall survival (OS),
rogression-free survival (PFS), and incidence of
rades II to IV acute graft-vs-host-disease (GVHD)
2]. We found no signiﬁcant difference in OS, PFS, or
hronic GVHD, between the HLA DR15-positive
ersus -negative groups in any disease or donor rela-
ion subgroups. However, the HLA DR15-positive
yeloid malignancy group experienced a signiﬁcantly
ower incidence of acute GVHD grades II to IV: 23%
ersus 42% (P  .041). We concluded that HLA
R15 is associated with a reduced risk of acute
VHD in patients with myeloid malignancies.
In contrast, Stern et al found that patients with
R15 had an OS advantage due to a reduced relapse
ate without a difference in transplant-related mortal-
ty. In addition, they describe a lower rate of grade
I-IV acute GVHD (37% vs. 48%, P .18) in patients
ith DR15. Their analysis, stratiﬁed by lymphoid
ersus myeloid malignancies, found a signiﬁcantly re-
uced risk of acute GVHD in patients with lymphoid
alignancies but no difference in patients with my-
loid malignancies.
Stern et al have suggested several reasons for the
isparity in ﬁndings between our 2 studies: the Swiss
ohort received predominantly peripheral blood stem
ells, 17% received nonmyeloablative conditioning
egimens, no patients received triple-agent GVHD
rophylaxis, and they excluded matched unrelated do-
ors and excluded patients with serologic HLA-DRB1
yping. In addition to these differences recognized by
tern et al, we emphasize that the Roswell Park cohort
ocused exclusively on myeloid malignancies treated
ith myeloablative conditioning regimens to better
xamine the immunobiologic hypothesis that DR15
referentially presents immunodominant myeloid an- Bigens. The Swiss patients included 47% myeloid ma-
ignancies; results were stratiﬁed by lymphoid versus
yeloid malignancies for acute GVHD and death
rom relapse, but not for OS. We have presented data
hat there are important differences in immunobio-
ogic outcomes based on differential antigen presen-
ation in myeloid versus lymphoid malignancies in
atients with HLA DR4 antigen [3,4] (manuscript in
reparation).
We support collaborative studies of larger central
egistry datasets to explore clinical outcomes by HLA-
RB1 antigen status in HLA-matched allogeneic
tem cell transplantation.
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